NO20056042L - Forbindelser som er anvendelige til behandling av Alzheimers sykdom samt formuleringer inneholdende disse - Google Patents

Forbindelser som er anvendelige til behandling av Alzheimers sykdom samt formuleringer inneholdende disse

Info

Publication number
NO20056042L
NO20056042L NO20056042A NO20056042A NO20056042L NO 20056042 L NO20056042 L NO 20056042L NO 20056042 A NO20056042 A NO 20056042A NO 20056042 A NO20056042 A NO 20056042A NO 20056042 L NO20056042 L NO 20056042L
Authority
NO
Norway
Prior art keywords
alzheimer
disease
treatment
well
formulations containing
Prior art date
Application number
NO20056042A
Other languages
English (en)
Inventor
Luisella Verotta
Gabriele Fontana
Ezio Bombardelli
Original Assignee
Indena Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena Spa filed Critical Indena Spa
Publication of NO20056042L publication Critical patent/NO20056042L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/743—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups having unsaturation outside the rings, e.g. humulones, lupulones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/723—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic
    • C07C49/727—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system
    • C07C49/733—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system having two rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Floroglukinosalter med acetylcholinesterase-inhiberende alkaloider samt fremgangsmåter for fremstilling derav. Nevnte salter er anvendehge til behandling av depresjon og Alzheimers sykdom og kan bh adminisfrert som konvensjonelle farmasøytiske formuleringer eller som ttansdermale preparater med konfrollert fiigjøring.
NO20056042A 2003-05-30 2005-12-19 Forbindelser som er anvendelige til behandling av Alzheimers sykdom samt formuleringer inneholdende disse NO20056042L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001098A ITMI20031098A1 (it) 2003-05-30 2003-05-30 Composti utili nella terapia del morbo di alzheimer e formulazioni che li contengono
PCT/EP2004/005644 WO2004106275A2 (en) 2003-05-30 2004-05-26 Compounds useful in the therapy of alzheimer’s disease and formulations containing them

Publications (1)

Publication Number Publication Date
NO20056042L true NO20056042L (no) 2005-12-19

Family

ID=30131121

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20056042A NO20056042L (no) 2003-05-30 2005-12-19 Forbindelser som er anvendelige til behandling av Alzheimers sykdom samt formuleringer inneholdende disse

Country Status (16)

Country Link
US (1) US20070010507A1 (no)
EP (1) EP1638914A2 (no)
JP (1) JP2007505152A (no)
KR (1) KR20060012316A (no)
CN (1) CN1795158A (no)
AU (1) AU2004242838A1 (no)
BR (1) BRPI0410703A (no)
CA (1) CA2527354A1 (no)
DE (1) DE602004010100T2 (no)
EC (1) ECSP056190A (no)
IL (1) IL172213A0 (no)
IT (1) ITMI20031098A1 (no)
MX (1) MXPA05012826A (no)
NO (1) NO20056042L (no)
RU (1) RU2005136984A (no)
WO (1) WO2004106275A2 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060287554A1 (en) * 2005-06-21 2006-12-21 Madsen Kevin K Process for producing inorganic salts of hop acids
US20070104771A1 (en) * 2005-09-23 2007-05-10 Jay Audett Transdermal galantamine delivery system
EP2236160A3 (en) * 2009-03-31 2011-12-14 Sanovel Ilac Sanayi ve Ticaret A.S. Modified release dimebolin formulations
BR112012007557A2 (pt) * 2009-10-02 2017-05-02 Blanchette Rockefeller Neurosciences Inst alterações anormais de processamento de isozimas de pkc em células periféricas da doença de alzheimer
DE102010024105A1 (de) 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
CN108135872A (zh) * 2015-07-31 2018-06-08 约翰霍普金斯大学 用于治疗认知缺陷的谷氨酰胺拮抗剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE253033T1 (de) * 1998-02-13 2003-11-15 Schwabe Willmar Gmbh & Co Stabile hyperforin-salze, verfahren zu ihrer herstellung und verwendung zur therapie der alzheimerschen krankheit
AU3738700A (en) * 1999-03-15 2000-10-04 Shaman Pharmaceuticals, Inc. Stabilized bicyclo(3.3.1)nonenes and methods of use
KR20040054738A (ko) * 2001-10-26 2004-06-25 메타프로테오믹스, 엘엘씨 시클로옥시게나제-2의 발현 및/또는 활성의 상승 억제를나타내는 쿠르쿠미노이드 조성물

Also Published As

Publication number Publication date
CN1795158A (zh) 2006-06-28
BRPI0410703A (pt) 2006-06-13
CA2527354A1 (en) 2004-12-09
RU2005136984A (ru) 2006-03-27
WO2004106275A2 (en) 2004-12-09
DE602004010100D1 (de) 2007-12-27
KR20060012316A (ko) 2006-02-07
IL172213A0 (en) 2009-02-11
DE602004010100T2 (de) 2008-09-18
EP1638914A2 (en) 2006-03-29
JP2007505152A (ja) 2007-03-08
ITMI20031098A1 (it) 2004-11-30
ECSP056190A (es) 2006-08-30
WO2004106275A3 (en) 2005-03-17
ITMI20031098A0 (it) 2003-05-30
US20070010507A1 (en) 2007-01-11
MXPA05012826A (es) 2006-02-13
AU2004242838A1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
NO20082530L (no) Imidazopyraziner som proteinkinaseinhibitorer
NO20071912L (no) Donepezilsalter egnet for fremstilling av farmasoytiske sammensetninger.
NO20055496L (no) Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer
NO20055092L (no) Substituerte pyrimidioner
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
GB0211649D0 (en) Organic compounds
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
HUP0401590A2 (hu) Eljárások allogén sziget átültetés védelmére oldható CTLA4 mutáns molekulák alkalmazásával
NO20040547L (no) Amino-ftalazinonderivater aktive som kinaseinhibitorer, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende disse.
CA2366932A1 (en) Cyclic protein tyrosine kinase inhibitors
MXPA04000920A (es) Derivados de aminoisoxazol activos como inhibidores de la cinasa.
MY145790A (en) Composition
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
SI1730147T1 (sl) Substituirane triazaspiro dekan onskespojine za zdravljenje obezitete
NO20073059L (no) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
NO20056042L (no) Forbindelser som er anvendelige til behandling av Alzheimers sykdom samt formuleringer inneholdende disse
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
MXPA05009719A (es) Derivados de biciclo-pirazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden.
WO2005014572A8 (en) Pyrimidylpyrrole derivatives active as kinase inhibitors
NO20073176L (no) Nye medikamenter for behandling av luftveissykdommer
NO20056005L (no) Terapautiske midler
ES2179729A1 (es) Forma farmaceutica solida de administracion oral dispersable en agua, que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica.
WO2003066806A3 (en) Therapeutic use of aziridino compounds
NO20040471L (no) 5,6,6a,1 1b-tetrahydro-7-oksa-5-azabenzo[c]fluoren-6-karboksylsyrederivater som NMDA-antagonister